# EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

> **Open Intelligence Dossier** · First detected: 2026-08-18 13:07 UTC · Category: Business

## Executive Summary
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction." is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.


Outlets currently covering the story include The Boston Globe and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| The Boston Globe | Eyepoint study results for vision treatment disappoint, but Watertown-based company still sees promise | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxQT2ROeFVoUG1fRFQ4TWxOUTJmSUZUN3BCUEtNbVpuTFNpWEtDb19SVzFtYmFJTmRTQ2RmdFpTdnQ2VjFPendHYjNEQjVteVN6WFc3enkxa3FZU1FUYjBybnpxVlBIcUVxc09Da2pQdlVRb3MtRTRzNlZiX2pYZElESW5kbk9nRzg?oc=5) |
| BioPharma Dive | EyePoint plummets on pivotal data for main drug | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDJZTzkzbFZCVHliemRRNU9ITjF4N3g3NTM4UWZxSjl2OUMzOVBtZUR5MER6WEtCNno0UUVhOE9FSTd5bDRyT21XYVN3enpNSFZHWDh0OU5ZVllZaGJDTHNSQWY2ZlhybUMtR1FSR2t5X0IyQV9uSm9peEYwUmdfVVRFRVJpc215YmdFNlFOMnE?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-08-18/eyepoint-stock-craters-69-after-drug-trial-failure-it-may-be-an-overreaction*